Physician
Oncology
Dr. Mitesh J. Borad, MD
|
|
Give Review
Doctor Mitesh J. Borad, MD practices Oncology. He researched medicine at Rutgers New Jersey Medical School. Rutgers New Jersey Medical School is ranked 76 in research and 0 in primary care medicine Mitesh J. Borad, MD is a published physician. He published 35 publications, including: 'Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophage...' Mitesh Borad accepts Medicare payments and is listed with Medicare.gov.
Publications
- Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.
- Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.
- Phase 1 Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors.
- Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.
- Cholangiocarcinoma: molecular pathways and therapeutic opportunities.
- Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic Cancer.
- Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
- Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid Tumors.
- Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid Tumors.
- Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma.
- Preoperative chemoradiation and IOERT for unresectable or borderline resectable pancreas Cancer.
- A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid Tumors.
- Effect of selection of QTc formula on eligibility of Cancer patients for phase I clinical trials.
- Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors.
- Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients...
- Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial.
- Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors.
- Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies.
- Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors.
- Reduced Acute Bowel Toxicity in Patients Treated With Intensity-Modulated Radiotherapy for Rectal Cancer.
- Patient willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials.
- Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory Cancers.
- Safety studies on intrahepatic or intratumOral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates.
- A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patie...
- Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
- Localized gastric or gastroesophageal Cancer - chemoradiation is a pertinent component of adjuvant treatment for patients at high risk of relapse.
- Skeletal metastases in pancreatic Cancer: a retrospective study and review of the literature.
- Marantic Endocarditis Associated with Pancreatic Cancer: A Case Series.
- The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple Myeloma tumor cells to chemotherapeutic agents.
- Whole Genome Analyses of a Well-Differentiated Liposarcoma Reveals Novel SYT1 and DDR2 Rearrangements.
- Advances in systemic therapy for advanced pancreatoBiliary malignancies.
- Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple Myeloma.
- Isolated supraclavicular lymph node metastasis in Pancreatic adenocarcinoma: a report of three cases and review of the literature.
- Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophage...
Schools
University of Medicine And Dentistry of New Jersey Newark
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Tulane University -
Cedars-Sinai Medical Center -
Rutgers New Jersey Medical School
Hospital
-
Mayo Clinic - Phoenix/Scottsdale, Arizona
Drug Facts
| NPI NUMBER | 1801850573 | |
| NPPES Provider LastName | BORAD | |
| NPPES Provider FirstName | MITESH | |
| NPPES Provider ZIPCode | 852595404 | |
| NPPES Provider State | AZ | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 90.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1801850573 |
| Last Name Of The Provider | BORAD |
| First Name Of The Provider | MITESH |
| View All |
Similar Doctors
|
|
Dr. Giraldo Kato, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patrick J. Donovan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thai H. Ho, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael S. Gordon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Donald W. Northfelt, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Helen J. Ross, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nandita Khera, MD
This Doctor is OpenDoctor Recommended.
|